CSTL — Castle Biosciences, Inc. stock price, charts and financials

QT78Castle Biosciences, Inc.

Castle Biosciences, Inc. (NASDAQ: CSTL) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
32.82
+0.79+2.48%
OverviewShort InterestFilings
CSTLQT78Castle Biosciences, Inc.·NASDAQ
32.82+2.48%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
PSNL+2.40%$14.50FLGT-0.67%$19.01CDNA+2.31%$47.77NEOG-0.32%$11.43PRE-0.77%$18.12MYGN+1.38%$3.31VCYT-1.95%$46.30BLLN+4.93%$98.00
Snapshot
Index-P/E-EPS (ttm)-0.66Insider Own2.46%Shs Outstand30.55MPerf Week14.39%
Market Cap978.50MForward P/E-EPS next Y-1.01Insider Trans-40.20%Shs Float26.99MPerf Month30.42%
Enterprise Value953.03MPEG0.49EPS next Q-0.33Inst Own94.13%Short Float5.27%Perf Quarter66.48%
Income-19.47MP/S2.74EPS this Y-114.59%Inst Trans-Short Ratio3.63Perf Half Y-1.14%
Sales357.28MP/B2.07EPS next Y28.36%ROA-3.46%Short Interest1.42MPerf YTD-17.66%
Book/sh-P/C22.84EPS next 5Y-ROE-4.15%52W High45.37 -27.66%Perf Year62.10%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-6.31%52W Low18.16 80.76%Perf 3Y90.77%
Dividend Est.-EV/EBITDA-Sales past 3/5Y35.92% 40.42%Gross Margin77.26%Volatility6.01% 5.62%Perf 5Y-54.14%
Dividend TTM-EV/Sales2.67EPS Y/Y TTM-206.45%Oper. Margin-8.99%ATR (14)1.52Perf 10Y-
Dividend Ex-Date-Quick Ratio5.85Sales Y/Y TTM7.83%Profit Margin-5.43%RSI (14)77.38Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.04EPS Q/Q-146.67%SMA2022.26%Beta1.01Target Price39.00
Payout0.00%Debt/Eq0.08Sales Q/Q20.93%SMA5035.02%Rel Volume0.57Prev Close32.03
Employees883LT Debt/Eq0.08EarningsNov 02SMA20010.16%Avg Volume423.01KPrice32.82
IPO DateJul 25, 2019Option/ShortYes / YesEPS/Sales Surpr.82.81% 20.07%Net Debt/EBITDA7.87Volume241,774Change2.48%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-03-26ReiteratedBTIGBuy$50 → $44
Jul-31-26ReiteratedRobert W. Baird$43 → $36
Jun-24-26InitiatedRoth CapitalBuy$40
May-29-26ReiteratedKeyBancOverweight$50 → $35
Apr-20-26ReiteratedCanaccord GenuityBuy$50 → $40
Jan-29-26ReiteratedKeyBancOverweight$36 → $50
Jan-26-26ReiteratedGuggenheimBuy$43 → $47
Jan-12-26ReiteratedLake StreetBuy$52
Jan-05-26ReiteratedGuggenheimBuy$30 → $43
Dec-22-25ReiteratedCanaccord GenuityBuy$42 → $50
Latest News
Aug-04-26
Aug-04-2602:15AM
Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL)defenseworld.net
Aug-03-26
Aug-03-2606:35AM
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44Benzinga
Jul-31-26
Jul-31-2603:53AM
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcriptseekingalpha.com
Jul-30-26
Jul-30-2609:04PM
Castle Biosciences (NASDAQ:CSTL) Surges After Smashing Q2 Estimates and Raising GuidanceChartMill
07:00PM
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimateszacks.com
06:06PM
Castle Biosciences Q2 Earnings Call Highlightsmarketbeat.com
Jul-22-26
Jul-22-2607:00AM
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conferenceprnewswire.com
Jul-14-26
Jul-14-2604:30PM
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Testprnewswire.com
Jul-09-26
Jul-09-2607:00AM
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026prnewswire.com
Jun-25-26
Jun-25-2604:35PM
Castle Biosciences Announces Published Study In 'Dermatology And Therapy' Showing DecisionDx-Melanoma Test Outperforms MIA Nomogram In Predicting Sentinel Lymph Node Positivity RiskBenzinga
12:21PM
This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For ThursdayBenzinga
10:17AM
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For ThursdayBenzinga
08:44AM
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga
06:39AM
Roth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40Benzinga
Company

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.

Ownership
Total institutional ownership94.13%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue358344332——————
Cost of Goods Sold Incl. D&A827160——————
Gross Profit276273272——————
Selling, General and Administrative Excl. Other244229200——————
Research and Development565252——————
Other Operating Expense93511——————
Operating Income-32-439——————
Interest Expense001——————
Unusual Expense
—————————
Non-Operating Income (Expense)131313——————
Net Income Before Taxes-19-3022——————
Income Taxes0-53——————
Consolidated Net Income-20-2418——————
Net Income From Continuing Operations-20-2418——————
Net Income-20-2418——————
EPS (Recurring)-0.66-0.830.66——————
EPS (Basic, Before Extraordinaries)-0.66-0.830.66——————
EPS (Diluted)-0.66-0.830.62——————
EBITDA-31138——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——42.98——————
Price To Sales Ratio2.753.282.25——————
Gross Margin77.0979.3681.93——————
Operating Margin-8.94-12.502.71——————
Net Margin-5.59-6.985.42——————
Shares Outstanding302928——————
Market Capitalization9851,128746——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$47.30$38.07$28.84$19.62$10.39● Close Price0.00M0.90M1.79M2.69M3.59MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
MAETZOLD DEREK JPres. & Chief Exec. OfficerAug 05 '26Sale30.683,575109,68519,607Aug 06
MAETZOLD DEREK JPres. & Chief Exec. OfficerAug 05 '26Option Exercise2.392,5466,08524,025Aug 06
MAETZOLD DEREK JPres. & Chief Exec. OfficerAug 04 '26Sale31.1135,4411,102,54520,080Aug 06
MAETZOLD DEREK JPres. & Chief Exec. OfficerAug 04 '26Option Exercise2.3920,35648,65141,835Aug 06
Juvenal Tobin WChief Commercial OfficerNov 24 '25Sale38.391,30149,94577,694Aug 06
Oelschlager Kristen MChief Operating OfficerAug 03 '26Sale29.778,586255,62213,288Aug 05
Juvenal Tobin WChief Commercial OfficerAug 03 '26Sale28.251,73048,87378,995Aug 04
MAETZOLD DEREK JPres. & Chief Exec. OfficerAug 03 '26Option Exercise2.3910,66425,48732,143Aug 04
MAETZOLD DEREK JPres. & Chief Exec. OfficerAug 03 '26Sale30.3518,493561,31821,479Aug 04
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 31 '26Option Exercise2.396,48015,48727,959Aug 04
Juvenal Tobin WChief Commercial OfficerJul 31 '26Sale29.3117,310507,30180,725Aug 04
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 31 '26Sale30.1510,153306,13321,479Aug 04
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 27 '26Sale24.169,002217,53111,812Jul 29
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 27 '26Option Exercise2.396,21414,85127,693Jul 29
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 14 '26Sale22.923,33876,50712,090Jul 16
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.